Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma: a Multicentre, Open-label, Randomised Phase 2 Trial

Conditions:   Effect of Drugs;   Quality of Life;   Chordoma;   Advanced Cancer Intervention:   Drug: Anlotinib Hydrochloride Sponsors:   Peking University People's Hospital;   Peking University Shougang Hospital;   Peking University Third Hospital;   3Peking University First Hospital;   Beijing Jishuitan Hospital;   People's Liberation Army General Hospital (301);   Beijing Cancer Hospital;   Cancer In stitute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials